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I.   Abstract  
  Opioids are commonly prescribed to relieve neuropathic pain after a spinal cord injury  
(SCI),4 but often fail to be effective due to an injury-induced state that mimics opioid tolerance.22 
Previous studies have shown that the analgesic effects of morphine can be restored if morphine is 
administered in combination with a dopamine D3 receptor agonist or a dopamine D1 receptor 
antagonist, demonstrating that dopamine receptor activity modulates the response to opioids after 
SCI.5  Therefore, it was hypothesized that SCI alters levels of dopamine and expression of its 
receptors in the brain and spinal cord and that these changes are associated with injury-induced 
morphine tolerance. Baseline nociceptive (pain) thresholds were measured in 8 uninjured and 16 
spinal cord injured rats before and after injection of morphine (2mg/kg) or saline (control). Rats 
were then randomized to have thresholds re-assessed after injection of morphine + pramipexole 
(PPX, D3 agonist), morphine + SCH 39166 (SCH, D1 antagonist), pramipexole, or SCH. 
Lumbar spinal cord and striatal brain tissue were collected from each animal and processed for 
metabolomics, targeted mass spectrometry (MS) and Western blot to identify, quantify and 
compare levels of dopamine and its metabolites and receptors across groups. Morphine alone 
increased sensory thresholds in all uninjured but only 33% of injured rats. Based on this data, 
animals were categorized as morphine responders (n=5) or nonresponders (n=10). Morphine + 
PPX and morphine + SCH increased sensory thresholds in all injured animals, while PPX and 
SCH alone had no effect. Striatal dopamine levels in injured morphine nonresponders were 
significantly decreased compared to uninjured animals. Dopamine levels in injured morphine 
responders compared to injured morphine nonresponders are currently being analyzed further. 
Metabolomics principal component analysis (PCA) of lumbar cord identified three clusters that 
corresponded to injured morphine responders, injured morphine nonresponders, and uninjured 
animals. Preliminary pathway analysis points to differences in phenylalanine, tyrosine, and 
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tryptophan biosynthesis between these groups. Full pathway analysis is ongoing, but data 
suggests that differential dopaminergic pathway expression in the CNS following SCI is 
associated with morphine responsiveness. This provides early evidence that the dopamine system 
may provide a target for intervention in opioid resistant pain states.  
  
II.   Background and Introduction  
Approximately 17,700 new cases of spinal cord injury are recorded in the United States 
each year.19  Neuropathic pain presents in 53% of these cases, a prevalence rate greater than both 
musculoskeletal and visceral pain after SCI.9  Quality of life is typically significantly reduced in 
patients experiencing chronic neuropathic pain,3 especially when combined with SCI. When 
surveyed, these patients often report dysesthesia, allodynia, hyperalgesia, and other neuropathic 
symptoms that can persist for years after injury and mechanical recovery.4,15  Neuropathic pain is 
also known to result in sleep disturbances and, consequently, heightened anxiety and 
depression.20  One study found that as many as 43% of neuropathic pain patients suffered some 
form of unemployment as a result of their pain, often citing sleep deprivation as a major factor.18 
These physical, psychological, and sociological barriers demand a safe and effective treatment 
for neuropathic pain to restore quality of life for SCI patients.  
Neuropathic pain remains one of the most difficult conditions to treat.25 The potent 
analgesic property of opioids14 has made them a common therapy for neuropathic pain after 
SCI,12 but increased awareness of their negative side effects has assigned them clinical 
ambivalence in recent decades. While the increase in opioid prescriptions from 76 million in  
1991 to 219 million in 201121 speaks to their availability and clinical relevance, the potential to 
develop tolerance and addiction to the substance over longer periods of use remains a primary 
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deterrent for opioid treatment under chronic pain conditions.6 This tolerance from months of 
opioid treatment can lead to dangerously elevated doses, in some cases as high as three times the 
dosage of opioid-naïve patients11, to achieve adequate analgesia while also increasing the 
likelihood of addiction from repeated exposure. Cases of dampened opioid analgesia in 
postoperative neuropathic pain also suggests that the injury itself can facilitate conditions for 
opioid tolerance without recent exposure to the drug.5    
While hypotheses vary, it is clear that the development of a drug or drug combination that 
provides analgesia in response to neuropathic pain after SCI without increasing risk of tolerance 
is necessary to improving quality of life and overall patient outcomes. The relationship between 
µ-opioid receptors (MORs) and dopamine 3 receptors (D3Rs) and dopamine 1 receptors (D1Rs) 
provides a potential therapeutic mechanism. MORs, D3Rs, and D1Rs have all been shown to be 
present in the same neurons within the spinal dorsal horn,1,10 an area involved in processing 
peripheral painful stimuli. MOR or D3R activation inhibits phosphorylation of the membrane, 
allowing these nociceptive neurons to remain sensitive to opioid binding. D1R activation offers 
an opposing action by stimulating opioid receptor phosphorylation and desensitizing the 
membrane to opioid binding.16  Opioid tolerance has been shown to result in an increased ratio of 
D1Rs to D3Rs, creating an imbalanced net effect that decreases membrane MOR availability and 
prevents morphine from binding to receptors that provide analgesia (Figure 1).7,20,23  D3R 
agonists and D1R antagonists function to reverse this effect.8  In a preliminary study, 33% (n=5) 
of the rat population received analgesia from morphine treatment after spinal cord injury while 
66% (n=10) did not, exhibiting a state of injury-induced morphine tolerance. When these 
morphine-tolerant rats were treated with a combination of morphine and pramipexole (D3 
agonist) or a combination of morphine and SCH39166 (D1 antagonist), a significant increase in 
analgesia was observed. This demonstrates that dopamine plays an important role in post-SCI 
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tolerance modulation, but does not reveal the injury’s direct effect on dopamine levels or if a 




Figure 1. Immunohistochemistry of the spinal dorsal horn. Panels A-D are all represented by the white 
box in panel E, showing colocalization of µ-opioid receptors (A), D1Rs (B), and D3Rs (C).  
  
Dopamine’s intimate relationship with the opioid receptor system provides the 
opportunity for an indirect approach to restoring morphine efficacy, but few studies have 
examined how an injury such as SCI alters the quantity of available dopamine. A sharp decline in 
D1Rs in the periaqueductal gray (PAG) region of the brain was reported by Voulalas, et al,26 but 
literature regarding cortical levels of dopamine following SCI is scarce. Dopamine and key 
enzymes involved in dopamine formation such as tyrosine hydroxylase also appear to decrease 
within the cord in response to SCI.13  These data highlight the link between SCI-induced 
dopaminergic changes and the morphine tolerance that results from altered interaction with the 
opioid receptor system as described above. With the goal of improving drug efficacy and 
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decreasing risk of tolerance for opioidergic treatments, dopamine’s connection between spinal 
cord injury and opioid tolerance must be examined in greater depth. The current study aims to 
addresses the hypothesis that animals responsive to morphine will exhibit levels of DA and its 
metabolites similar to uninjured animals while those unresponsive to morphine will show 
comparatively decreased DA levels. In addition, SCI responders, nonresponders, and uninjured 
animals will express independent metabolite clustering.   
  
  
III.   Methods  
Animals  
  Female Long-Evans rats (N=24) weighing 200-225g were purchased from Charles River 
Laboratories (Wilmington, MA). Animals were maintained on a 12-hour light–dark cycle in a 
temperature-controlled environment with food and water available continuously. Rats were 
housed in pairs prior to surgery but individually afterward. All experimental procedures 
complied with the National Institute of Health (NIH) guidelines for animal care and were 
approved by the East Carolina University Institutional Animal Care and Use Committee.  
Lesion  
  Animals were randomly assigned to uninjured (n=8) or SCI (n=16) groups prior to 
surgery. A contusive spinal cord injury was produced using a microprocessor-controlled 
PCI3000 Precision Impactor (Hatteras Instruments, Cary, NC) with a 1mm round, blunt impact 
tip. Rats were temporarily anesthetized via Isoflurane (1-3% to effect) inhalation and secured 
stereotactically (Stoelting Co, Wood Dale, IL). After dorsal midline incision and vertebral 
column exposure, a spinous process and vertebral lamina were removed between T12-L1. The 
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contusion injury (velocity of impact = 0.8m/sec, depth of impact = 1.5mm, dwell time = 85ms) 
was induced 0.5mm right of midline. Deep tissue and muscles were sutured and skin was stapled 
to close. Since the nature and location of this injury can lead to bladder dysfunction24, animals 
showing bladder distention were externally manipulated to achieve adequate urination until 
function returned. One rat died during surgery.  
Post-SCI Assessment  
  Hindlimb motor function was assessed weekly in injured animals using the Basso, 
Beattie, Bresnahan (BBB) Locomotor Scale until pain threshold testing. The BBB scale assesses 
hindlimb movements, weight-bearing coordination, toe clearance, and trunk stability. Only 
animals that scored 15 points (range=0-21) or higher underwent nociceptive testing to ensure that 
motor impairment was not contributing to changes in nociceptive thresholds. Animals were 
scored while experimenters observed them for 4 minute in an open environment.   
 Nociceptive Testing  
  A TF-1 unit (Columbus Instruments, Columbus OH) was used to measure tail flick 
response time as a measure of nociceptive threshold. Each rat was covered with a pouch while its 
tail was placed on the heat conduit 4cm from the tip. A 10s cutoff latency was employed as a 
precaution. Average latency was calculated over 3 trials. Tail flick testing occurred 30min after 
drug injection. Testing occurred as follows. Prior to surgery all animals were assessed for their 
baseline thermal thresholds. Uninjured rats were randomized to receive either morphine  
(2.0mg/kg) or saline (0.9%). Half of the rats in each group were then assigned either PPX  
(0.1mg/kg) or SCH (0.1mg/kg) while the other half were assigned either morphine (2.0mg/kg) + 
PPX (0.1mg/kg) or morphine (2.0mg/kg) + SCH (0.1mg/kg). After surgery and 3 weeks of BBB 
testing, SCI rats were randomized to receive morphine or saline as described previously. SCI rats 
  9  
lacking an analgesic response following morphine injection were categorized as morphine 
nonresponders (n=10) while the others remained morphine responders (n=5). Using matched 
pairing for morphine responsiveness animals were randomly assigned either PPX and morphine + 
PPX or SCH and morphine +SCH. All drugs were administered with a subcutaneous injection with 
a 48hr window between each injection.  
Tissue Collection  
  After testing was complete, animals were deeply anesthetized and decapitated. The 
striatum was dissected bilaterally for mass spectrometry and Western blot analysis. Three 
sections of spinal cord were dissected: the area directly surrounding the injury for lesion analysis 
and two sections below injury for mass spectrometry and Western blot analysis. Sections for 
lesion analysis were placed into 4% paraformaldehyde while sections for mass spectrometry and 
Western blot were flash frozen in liquid nitrogen until placed in temporary storage.   
Lesion Analysis  
  Injured spinal cord sections were stored in 4% paraformaldehyde for 24 hours followed 
by 30% sucrose for 48 hours. 75µm longitudinal sections were cut using a Leica 2400 freezing 
microtome (#030G, Matsunami, Bellingham, WA). Sections were placed in PBS before 
mounting on TruBond 380 adhesive microscope slides. Slides were stained with cresyl violet and 
imaged using an Olympus BX51 microscope with an Olympus DP70 camera. For each animal, 
the section of cord with the largest lesion area was used to quantify the extent of gray matter 
damage. Using Image J (NIH) after setting the scale, the max width and length of the lesion was 
measured in millimeters(mm). Width and length were then multiplied together to calculate lesion 
area. The total number of sections displaying the lesion were also summed.  
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Western Blot  
  Tissues were homogenized using an Omni TH tissue homogenizer (#TH01 Omni  
International, Kennesaw, GA) at a ratio of 10µl buffer to 1mg tissue. Homogenization buffer was 
comprised of RIPA buffer (#R0278 Sigma-Aldrich, St. Lois, MO) with 10% 10X protease and  
1% phosphatase inhibitors (#87786 Thermo Fisher Scientific, Waltham, MA and #P5726 Sigma- 
Aldrich, St. Lois, MO). Following homogenization, samples were centrifuged (13,000 rpm, 4°C 
15 min) and supernatants were aliquoted and stored at -80°C. Protein concentrations were 
determined using a Pierce BCA Protein Assay kit (#23227 Thermo Fisher Scientific, Waltham, 
MA). The 96 well assay plate was read at 562 nm using an Infinite M200 microplate reader and 
i-control software (Tecan Trading AG, Mannedorf, Switzerland).  
For Western blots, 20 µg of each lumbar spinal cord and striatum samples were denatured 
using 2 x Laemmli buffer (#1610737 Bio-Rad Hercules, CA) containing 5% β-mercaptoethanol 
and 1% SDS at 96°C for 10 min. Samples were loaded onto an Any kD Criterion TGX StainFree 
Protein Gel. (#5671125 Bio-Rad Hercules, CA) and allowed to run for40 minutes at 200V.  
The gel was then activated with UV light for 45 seconds using the BioRad ChemiDoc Imaging 
System (#12003153 Bio-Rad Hercules, CA) The proteins were transferred to a low fluorescent  
PVDF membrane using the Trans-Blot Turbo RTA Midi LF PVDF Transfer Kit (#170-4275, 
Bio-Rad, Hercules, CA) and the Trans-Blot Turbo (#1704150 Bio-Rad Hercules, CA) on the 1 
midi gel turbo setting. An image was taken of the stain-free blot for calculation of total protein 
using the BioRad ChemiDoc. Membranes were then blocked using Odyssey Blocking Buffer in 
TBS (#927-50000 LI-COR Licoln, NE) and probed with primary and secondary antibodies. 
Fluorescence imaging was performed using the Odyssey Clx imaging system (#9140 LI-COR 
Lincoln, NE).  
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Antibodies  
  The primary antibodies used were anti-dopamine receptor D1 (Bioss bs-1007r 1:500 
Woburn, MA) and anti-dopamine receptor D3 (Abcam ab155098 1:1000 Cambridge, MA). The 
secondary antibody used was IRDye 800CW got anti-rabbit (LI-COR Biosciences 926-32211, 
1:30,000 and 1:15,000 Lincoln, NE).  
Tissue Preparation  
  Below-level lumbar cord and striatum samples were transferred to bead tubes, 400µl of 
methanol, and 10µl of deuterated dopamine were added. Samples were homogenized using a 
bead mill homogenizer (Fisherbrand 15-340-163) for 10 seconds and then sonicated for 60 
seconds. Tubes were centrifuged at 12,000 rpm for 10 mins at 4°C and supernatant was 
collected. Extracted samples were stored at -80°C until further processing. Prior to analysis, 
samples were dried down using a nitrogen dryer and resuspended in 200 µl of 50:50 
methanol:water with 0.1% formic acid.  
Untargeted Metabolomics LC/MS  
An Eksigent 425 microLC/SCIEX 5600+ triple time-of-flight mass spectrometer was 
used to conduct untargeted analysis. A Halo C18 0.5 x 50 mm 2.7 µm column was used for 
separation of the analytes on the micro LC. The flow rate was 10 µl/min and 5 µL of sample was 
injected. Mobile phase A: water with 0.1% formic acid and mobile phase B: acetonitrile. A linear 
gradient was utilized with a flow rate of 10 µL/min where the gradient started with 10% B for 2 
min, increased to 90% B for 15 min, held for 5 min, dropped to 10%B over 2 min and 
equilibrated for 10 min for a total run time of 30 min.  
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Data was acquired for MS and MS/MS analysis using independent data acquisition for the 
topmost abundant 20 ions in positive ionization mode. The scan range for MS was 80-1250  
Da. Principal component analysis (PCA) and t-tests were conducted using MarkerView 1.3.1.  
Putative metabolite/pathway identification was performed by using HMDB.ca database  
(molecular weight tolerance ± 0.05 DA, Adduct type: M+H, and M+Na) to identify peaks. 
MetaboAnalyst.ca was utilized to conduct pathway analysis (Fisher’s Exact Test and 
relativebetweenness centrality, rattus norvegicus pathway library).  
Targeted LC/MS  
A ThermoSci hypersil gold 50 x 3 mm column was used for separation of the analytes on 
an Exion HPLC. The column temperature was maintained at 32°C. A gradient was used to 
separate the compounds using mobile phase A: 95:5 water with 0.1% formic acid:acetonitrile and 
mobile phase B: acetonitrile. A linear gradient was performed as follows: 0% B for 2 min, 90% B 
for 9 min, 90% B for 1 min, 0% B for 1 min, hold at 0% B for 5 min for a total run time of 18 
min. The flow rate was 0.3 mL/min and 5 µL of sample was injected. MS-MS analysis was 
conducted using an AB SCIEX 3200 triple quadrupole mass spectrometer. The mass 
spectrometer was in positive ionization mode and analysis was conducted using multiple reaction 
monitoring (MRM). The source parameters were set to a curtain gas 50 psi; heater gas 50 psi, ion 
spray voltage 5500 V; and source temperature 500 °C. The instrument parameters were 
optimized using direct infusion of each analyte using a split tee injection with the LC flow. Each 
targeted parent ion and two fragment ions are listed along with the corresponding retention time.  
SCIEX Analyst software was used for instrument control. Confirmation analysis was performed 
using MultiQuant where the calibrators and quality controls were carried through the same 
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processes as the specimens being tested. Least squared regression with 1/x weighing was used to 
evaluate the linearity with adequate compensation for heteroscedasticity during all experiments.  
Statistical Analysis  
Metabolomics and mass spec analysis and software are described above. Tail flick results 
are presented as percent analgesia, which is calculated as maximum possible effect (MPE) using 
the following formula MPE = [(test latency − baseline latency)/(cutoff latency − baseline 
latency)]*100. A one-way ANOVA was used to assess effect of drug condition. Holm-Sidak 
multiple comparison test was used to compare morphine alone to each drug condition. Lesion 
data was analyzed using unpaired t-tests. Western blot data was normalized to total protein and 
normalized signal intensity was analyzed using an unpaired t-test to examine differences between 
morphine responsive and nonresponsive rats. Data are presented as means ± SEM. Differences at 
p<0.05 were considered significant. Analyses were done using Prism 7 v. 7.02 (GraphPad 
Software, Inc, LaJolla, CA).   
  
  
IV. Results  
   Morphine alone provided analgesia in only 33% (n=5) of rats after SCI. Morphine +  
PPX and morphine + SCH both significantly restored opioidergic pain relief in the other 66% 
(n=10) of rats previously not responsive to morphine. Isolated administration of morphine, PPX, 
and SCH did not restore analgesia in injured nonresponders (Figure 3). Morphine, morphine + 
PPX, and morphine + SCH all facilitated significantly increased sensory thresholds above 
controls in uninjured rats (Figure 2). Saline did not provide any remarkable analgesia in any 
group.  
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                                   Uninjured                                                            SCI  
 
Figure 2. Yellow bar graph depicts nociceptive thresholds for uninjured rats (n=8) in each given drug 
condition. Morphine provided significantly improved analgesia compared to saline control.  SCI graph 
shows analgesia for all injured rats (n=15) in each given drug condition. Only 5 rats achieved analgesia 












             
   p<0.01   
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Figure 3.  Graph of only injured morphine nonresponders. Morphine + PPX and morphine + SCH 
restored analgesia after failure to respond to morphine alone (see Figure 2).  
  
  
Principle Component Analysis (PCA) of lumbar cord samples displayed independent 
clustering across SCI responders, nonresponders, and uninjured groups with the exception of one 
responder sample (Figure 4). PCA of striatum tissue showed tight clustering of samples except 
for one nonresponder sample which clustered with uninjured samples (Figure 5). Significant 
metabolites were identified between groups with a t-test (p<0.05) and tentatively identified. 
Comparing groups, 83 metabolites were present in differing quantities between uninjured and 
injured lumbar cord samples. Tentative identities included enkephalin and homovanillic acid 
(HVA). A total of 39 metabolites varied between responders and nonresponders in the lumbar 
cord. Tentative identities included HVA and 3-methoxytyramine (3-MT) (Table 1). Comparing 
uninjured and injured striatum samples revealed 135 metabolites that varied between the two 
  
p=0.0147   
p=0.0002   
SCI  
Nonresponders  
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groups. Tentative identities included dopamine and prostaglandins. A total of 27 metabolites 
varied between striatal responders and nonresponders. 3-Methoxytyramine remains a tentative 
identity for one of the metabolites (Table 2).  
  
Lumbar Cord  
  
    
Figure 4. PCA (left) shows independent clustering of lumbar cord samples across groups. Outlier in upper 
right quadrant showed abnormally small lesion size.  Total metabolite distribution (right) shows metabolic 
variability. Metabolites closer to the crosshair intersection were more commonly expressed across groups. 









    593 Metabolites   
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 Uninjured vs SCI  SCI responder vs SCI 
nonresponder  
Metabolites  83  39  
Tentative ID’s  Enkephalin 
Homovanillic acid*  
Homovanillic acid* 3 
-Methoxytyramine*  
Table 1. Notable metabolites tentatively identified in lumbar cord samples. Asterisks indicate metabolites 
closely related to dopamine (see Figure 10).  




Figure 5. PCA (left) shows independent clustering of striatum samples across groups. Outliers in upper 
and lower right quadrants showed abnormally large lesions.  Total metabolite distribution (right) shows 
metabolic variability. Metabolites closer to the crosshair intersection were more commonly expressed 






578 Metabolites       
  18  
 Uninjured vs SCI  SCI responder vs SCI 
nonresponder  
Metabolites  135  27  





Table 2. Notable metabolites tentatively identified in striatum samples. Asterisks indicate metabolites 
closely related to dopamine or dopamine itself (see Figure 10).  
  
Mass spectrometry showed dopamine quantity was significantly decreased in morphine 
nonresponders in the striatum, but DOPAC remained constant across groups (Figure 6). 
Dopamine in the lumbar spinal cord was significantly decreased in both responders and 
nonresponders (Figure 7).  
  
 
Figure 6. Targeted mass spectrometry for dopamine (left) and DOPAC (right) quantities in the striatum. 





p=0.02   
Striatum  
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Figure 7. Targeted mass spectrometry for dopamine quantity in the lumbar cord. Dopamine was 
decreased in both responders and nonresponders compared to uninjured animals.  
  
  
Western blot data shows D1R expression did not vary significantly across groups in the 
striatum and lumbar cord, but expression was slightly elevated in morphine responders in the 




p=0.03   
p<0.001   
  
Lumbar Cord  
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Figure 8. Western Blot signal intensities for D1R expression in striatum tissue. No significant variation in 





Figure 9. Western Blot signal intensities for D1R expression in lumbar cord tissue. No significant 






Lumbar Cord  
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V.   Discussion  
  Tail flick testing supported the position that certain populations are unresponsive to 
morphine post SCI. In this study, 66% (n=10) of injured rats fell into this nonresponder category. 
Morphine + PPX and morphine + SCH administration in subsequent SCI nonresponder testing 
were shown to reverse this trend, significantly restoring analgesia (p=0.002, p=0.0147) to 
animals who previously did not experience pain relief from morphine alone.   
  PCA data supported the hypothesis that SCI responders, nonresponders, and uninjured 
animals would express independent metabolite clustering. While this trend was shown 
throughout all groups in both the lumbar cord and striatum, outliers were seen. Spinal microtomy 
and imaging revealed that the SCI responder sample in the upper right quadrant of Figure 3 
displayed a lesion size of 0.4mm2 compared to the average size of 2.1mm2. The responder and 
nonresponder outliers in Figure 4 showed abnormally large lesions of 6.4mm2 and 3.2mm2 
compared to their respective group averages of 2.1mm2 and 1.7mm2. More data is required to 
establish a reliable connection between lesion size and PCA readings, but severity of injury 
offers an explanation for inconsistent metabolite expression. Overall metabolite distribution 
graphs will offer more meaningful data when individual data points are identified, but greater 
metabolite density in the lumbar cord distribution suggests that less variability in metabolite 
expression can be expected in this tissue after SCI compared to the striatum. This provides 
evidence of the need for future studies to identify specific changes in cortical dopaminergic 
biochemistry after SCI, as this data suggests these changes to be copious. Tentative metabolite 
identification continues to progress, but initial data showing variability in enkephalin, HVA, 
3MT, prostaglandins, and dopamine is promising. Differences between responders and 
nonresponders in metabolites such as HVA and 3-MT that are directly involved in dopamine 
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metabolism further supports the idea that dopamine plays a significant role in the development of 
SCI-induced tolerance.  
Dopamine Pathway  
 
Figure 10. Dopamine metabolic pathway.2 Boxed and starred metabolites indicate tentatively identified 
molecules that differ across uninjured, SCI responders, and SCI nonresponders in the lumbar cord and 
striatum (see Tables 1 and 2).  
  
  The similarity in dopamine quanitity in the striatum for uninjured and SCI responders 
supports the hypothesis. This relative decrease of striatal dopamine levels in nonresponders 
provides evidence that a decrease in dopamine quantity could contribute to morphine tolerance. 
The data showing both responders and nonresponders to experience a decrease in dopamine 
levels in the lumbar cord does not support the hypothesis and suggests that the corresponding 





*   
*   
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independent. It is still unknown if the decrease in spinal dopamine is due to the inability of 
dopamine to travel from the cortex to below the injury or if dopaminergic spinal neurons simply 
decrease their production after SCI. DOPAC quantity was anticipated to differ among groups due 
to its metabolic relationship to dopamine, but future mass spectrometry trials targeting other 
dopaminergic metabolites should be conducted to isolate specific changes among groups and 
tissues types.  
Constant D1R expression across groups and tissue types supports the idea that changes in 
dopamine production and metabolism are the main contributors to a state of SCI-induced 
morphine tolerance rather than receptor presence. This result does not parallel the expected 
upregulation of D1R in a state of morphine tolerance that was described earlier. Future Western 
blots examining D3R expression levels as well as comparing relative D1R and D3R 
concentration are needed to gain a better understanding of dopamine receptor dynamics within 
the context of morphine tolerance.  
  Medical intervention remains a major impetus for studying dopamine’s role in 
SCIinduced morphine tolerance. Increased opioid abuse, lowered life expectancies, and difficulty 
achieving analgesia in both acute and chronic pain patients certainly warrants an eventual pivot 
from animal models to human participants. If patient populations display similar resistance to 
opioid intervention as seen in this study, then the ability to categorize individuals as a morphine 
responder or nonresponder has the potential to reduce both healthcare costs and risk of opioid 
tolerance and addiction. Future studies will utilize targeted metabolomics to confirm metabolite 
identities and explore other effectors of the opioid system, providing an avenue through which 
morphine responsiveness categorization and expedited analgesic intervention can occur.  
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